| 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I … DL Gibbons, LQ Chow, DW Kim, SW Kim, T Yeh, X Song, H Jiang, ... Journal of Thoracic Oncology 11 (4), S79, 2016 | 145 | 2016 |
| Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status PG Baverel, VFS Dubois, CY Jin, Y Zheng, X Song, X Jin, ... Clinical Pharmacology & Therapeutics 103 (4), 631-642, 2018 | 128 | 2018 |
| Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort NH Segal, SHI Ou, A Balmanoukian, MG Fury, E Massarelli, JR Brahmer, ... European journal of cancer 109, 154-161, 2019 | 80 | 2019 |
| First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer NH Segal, J Naidoo, G Curigliano, S Patel, S Sahebjam, ... J Clin Oncol 36 (15_suppl), 3540, 2018 | 42 | 2018 |
| Molecular mechanism of polymer-assisting supersaturation of poorly water-soluble loratadine based on experimental observations and molecular dynamic simulations S Zhang, M Sun, Y Zhao, X Song, Z He, J Wang, J Sun Drug delivery and translational research 7, 738-749, 2017 | 24 | 2017 |
| Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies A Naing, J Infante, S Goel, H Burris, C Black, S Marshall, I Achour, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 22 | 2019 |
| Applications of model-based meta-analysis in drug development P Chan, K Peskov, X Song Pharmaceutical research 39 (8), 1761-1777, 2022 | 21 | 2022 |
| A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226 RA Juergens, D Hao, PM Ellis, D Tu, M Mates, C Kollmannsberger, ... Lung Cancer 143, 1-11, 2020 | 19 | 2020 |
| Exposure-response analyses of tremelimumab monotherapy or in combination with durvalumab in patients with unresectable hepatocellular carcinoma X Song, RK Kelley, AA Khan, N Standifer, D Zhou, KS Lim, R Krishna, ... Clinical Cancer Research 29 (4), 754-763, 2023 | 14 | 2023 |
| Evolving drug regulatory landscape in China: A clinical pharmacology perspective W Tang, Y Huang, D Zhou, Y Huang, Y Chen, S Ren, Y Li, S Wu, X Zhao, ... Clinical and Translational Science 14 (4), 1222-1230, 2021 | 13 | 2021 |
| Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors. X Song, M Pak, C Chavez, M Liang, H Lu, M Schwickart, ... Journal of Clinical Oncology 33 (15_suppl), e14009-e14009, 2015 | 12 | 2015 |
| First-line durvalumab+ monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC). ZA Wainberg, JR Diamond, G Curigliano, S Deva, JC Bendell, SW Han, ... Journal of Clinical Oncology 38 (4_suppl), 128-128, 2020 | 10 | 2020 |
| Population pharmacokinetics of durvalumab and fixed dosing regimens in patients with advanced solid tumors. P Baverel, V Dubois, C Jin, X Song, X Jin, P Mukhopadhyay, AK Gupta, ... Journal of Clinical Oncology 35 (15_suppl), 2566-2566, 2017 | 9 | 2017 |
| 203 Population pharmacokinetics of MEDI4736, a fully human antiprogrammed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors X Song, M Pak, C Chavez, M Liang, H Lu, AJ Blake-Haskins, PB Robbins, ... European Journal of Cancer 3 (51), S28, 2015 | 9 | 2015 |
| A randomized phase II study of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma MH Voss, AA Azad, AR Hansen, JE Gray, SJ Welsh, X Song, M Kuziora, ... Clinical Cancer Research 28 (14), 3032-3041, 2022 | 7 | 2022 |
| Impact of sex on clinical response in rheumatoid arthritis patients treated with biologics at approved dosing regimens L Fang, X Song, P Ji, Y Wang, J Maynard, S Yim, C Sahajwalla, M Xu, ... The Journal of Clinical Pharmacology 60, S103-S109, 2020 | 6 | 2020 |
| Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer W Chen, L Li, S Ji, X Song, W Lu, T Zhou European Journal of Clinical Pharmacology 76, 589-601, 2020 | 6 | 2020 |
| Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance M Hwang, YL Chia, Y Zheng, CCK Chen, J He, X Song, D Zhou, ... British Journal of Clinical Pharmacology 89 (5), 1601-1616, 2023 | 5 | 2023 |
| Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in combination with tremelimumab in patients with … M Tatipalli, X Song, M Pak, C Chavez, M Liang, H Lu, M Schwickart, ... Journal of Clinical Oncology 33 (15_suppl), e14010-e14010, 2015 | 4 | 2015 |
| 162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumors C Even, SB Goldberg, LL Siu, D Planchard, M Hwang, CCK Chen, J He, ... Annals of Oncology 32, S1451-S1452, 2021 | 3 | 2021 |
